GlassScriptPhysician profile
Mini Sara Cherian
NPI 1528205259
$544.98
in general payments reported to CMS, 2019-2025
18 companies · $19.96 in 2025
The $19.96 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $115 · 2023: $8.97 · 2025: $19.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $28.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $28.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.08 | 2019-2020 | |
| Dexcom, INC. | $60.11 | 2019 | |
| Sanofi-Aventis U.S. LLC | $57.72 | 2019-2020 | |
| Radius Health, INC. | $39.66 | 2019 | |
| Amarin Pharma, INC. | $39.33 | 2019 | |
| Abbvie INC. | $35.63 | 2019 | |
| Mannkind Corporation | $33.82 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.36 | 2019 | |
| Shire North American Group INC | $20.51 | 2019 | |
| Melinta Therapeutics, LLC | $20.36 | 2019 | |
| Beta Bionics, INC. | $19.96 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $19.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $19.43 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $17.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.93 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14.46 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $12.04 | 2019 | |
| Cequr Corporation | $8.97 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mini Sara Cherian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.